CD19 and B-cell non-Hodgkin lymphoma: In this analysis, we investigated the prevalence of the CD19 L174 allele and clinical outcome in a retrospective study of a B-cell lymphoma cohort treated with FMC63-anti-CD19-CAR-T cell therapy.